A novel urinary biomarker predicts 1-year mortality after discharge from intensive care

Table 4 Hazard ratios expressing the risk of death in models adding ACM128 to an established risk factor or biomarker

Risk factor to which ACM128 was added	Estimates for the risk factor to which ACM128 was added		Estimates for ACM128 in models with a second risk factor added
Risk factor to which ACM128 was added	HR (95% CI)	P	HR (95% CI)	P
Clinical risk factors
Charlson Comorbidity Index	1.20 (1.12, 1.28)	< 0.0001	2.24 (1.86, 2.71)	< 0.0001
Length of ICU stay	1.12 (0.99, 1.27)	0.078	2.38 (1.97, 2.87)	< 0.0001
Circulating biomarkers
BNP	1.15 (0.99, 1.34)	0.070	2.28 (1.87, 2.77)	< 0.0001
hsTnT	1.03 (0.87, 1.20)	0.76	2.40 (1.98, 2.91)	< 0.0001
ADM	1.06 (0.91, 1.23)	0.46	2.35 (1.93, 2.87)	< 0.0001
NGAL	1.04 (0.89, 1.21)	0.65	2.37 (1.93, 2.90)	< 0.0001
Urinary biomarkers
Albumin	1.14 (0.99, 1.32)	0.078	2.37 (1.96, 2.86)	< 0.0001

Abbreviations of the biomarkers are given in Table 2. The analysis includes 245 deaths and 1243 patients at risk. All models accounted for center (n = 15) as random effect and for sex, age, mean arterial pressure, glomerular filtration estimated from serum cystatin C, and diabetes mellitus. Association sizes are expressed for a 1-SD increment in the biomarkers except for the Charlson Comorbidity Index (+ 1 point)

ISSN: 1364-8535